BACKGROUND: We conducted a phase II study of @entity1206 and @entity900 chemotherapy in @entity1149 ( @entity1149 ) @entity1 who had failed previous chemotherapy, to assess the response and @entity137 of this combination chemotherapy. METHODS: Twenty-two @entity1 were enrolled from September 1999 to March 2001. The median age was 70 years. All @entity1 had a performance status of 2. @entity1206 was administered on days 1, 8 and 15, at a dose of 20 mg/m2; and @entity900 was given on day 1 at a dose of 50 mg/m2, every 4 weeks. RESULTS: Sixty-eight cycles of treatment were given, with a median of 3 cycles. All @entity1 were evaluable for @entity137 profile, and 21 @entity1 were evaluable for response rate. The major @entity137 was myelosuppression. Grade 3 or 4 @entity1398 occurred in 40.9% of the @entity1 , and grade 3 or 4 @entity417 occurred in 13.6% of the @entity1 during treatment. Uneventful @entity1398 occurred in 1 @entity1 . Other @entity137 were few and mild in severity. After 2 cycles of treatment, 2 of 21 @entity1 (9.5%) had a partial response (95% confidence interval 0%-22%). The median time of disease progression was 3.7 months, the median survival was 7.6 months, and the one-year survival was 12.3%. Median survival was 8.7 and 4.9 months in those @entity1 receiving this treatment as second-line and > or = third-line chemotherapy, respectively. CONCLUSIONS: @entity1206 and @entity900 salvage chemotherapy produced a modest anti- @entity5 response, a mild @entity137 profile, and reasonable survival in our elderly @entity1149 @entity1 with a poor performance status. This regimen deserves further study in elderly @entity1149 @entity1 who have failed previous chemotherapy.

Phase II study with XXXX and @entity900 in advanced @entity1149 after failure of previous chemotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine', 'Vinorelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']
@entity1206 :: (MESH:C030852,Chemical) :: ['vinorelbine']
